Duration and Efficacy of Azstarys (serdexmethylphenidate and dexmethylphenidate) on Adult ADHD Symptoms and Executive Function In Early Evening

Brief description of study

The purpose of this open-label treatment study is to extend the safety and efficacy evidence basis for Azstarys, a recently FDA approved ADHD product, in adults with ADHD and study adult executive functions throughout the day into early evening. Subjects will be in the study for approximately 8 weeks; 0-3 weeks (screening) 2 weeks (observation stabilization period) and 3 weeks (open-label azstarys / serdmph).

Clinical Study Identifier: s22-01003
ClinicalTrials.gov Identifier: NCT06000501

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.